304 related articles for article (PubMed ID: 15661398)
1. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
Sakajiri S; Kumagai T; Kawamata N; Saitoh T; Said JW; Koeffler HP
Exp Hematol; 2005 Jan; 33(1):53-61. PubMed ID: 15661398
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
[TBL] [Abstract][Full Text] [Related]
3. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
4. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis.
Takai N; Kawamata N; Gui D; Said JW; Miyakawa I; Koeffler HP
Cancer; 2004 Dec; 101(12):2760-70. PubMed ID: 15536623
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
6. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
Baradari V; Huether A; Höpfner M; Schuppan D; Scherübl H
Endocr Relat Cancer; 2006 Dec; 13(4):1237-50. PubMed ID: 17158768
[TBL] [Abstract][Full Text] [Related]
9. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB.
Nishioka C; Ikezoe T; Yang J; Komatsu N; Bandobashi K; Taniguchi A; Kuwayama Y; Togitani K; Koeffler HP; Taguchi H
Leuk Res; 2008 Feb; 32(2):287-96. PubMed ID: 17644177
[TBL] [Abstract][Full Text] [Related]
12. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
14. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
Hwang JJ; Kim YS; Kim MJ; Jang S; Lee JH; Choi J; Ro S; Hyun YL; Lee JS; Kim CS
Anticancer Drugs; 2009 Oct; 20(9):815-21. PubMed ID: 19644355
[TBL] [Abstract][Full Text] [Related]
15. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
16. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
Rikiishi H; Shinohara F; Sato T; Sato Y; Suzuki M; Echigo S
Int J Oncol; 2007 May; 30(5):1181-8. PubMed ID: 17390020
[TBL] [Abstract][Full Text] [Related]
17. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Jazirehi AR
Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
[TBL] [Abstract][Full Text] [Related]
18. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
[TBL] [Abstract][Full Text] [Related]
19. Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.
Ogawa T; Hayashi T; Tokunou M; Nakachi K; Trosko JE; Chang CC; Yorioka N
Cancer Res; 2005 Nov; 65(21):9771-8. PubMed ID: 16266998
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells.
Wu Y; Guo SW
Eur J Obstet Gynecol Reprod Biol; 2008 Apr; 137(2):198-203. PubMed ID: 17376583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
